🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Tirzepatide and fatty liver — SURPASS hepatic substudies Page 4

Tirzepatide and fatty liver — SURPASS hepatic substudies

MASHdoc_SA Thu, May 14, 2026 at 8:13 AM 19 replies 656 viewsPage 4 of 4
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
May 25, 2026 at 12:54 PM#16
NurseAsh_DET said:
Dose-response modeling for tirzepatide: Emax model fitting to the STEP/SURMOUNT dose-finding data shows: Semaglutide: ED50 ≈ 0.6mg, Emax ≈ -18%, Hill…

Same experience, arrived at from the opposite direction.

42 17SkepticalSean, Dr.CardioMD, EndoResFellow and 39 others
Reply Quote Save Share Report
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
May 26, 2026 at 5:48 PM#17
FDA_TrackerJim said:
The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Pushing back on FDA_TrackerJim here. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

41 16BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 38 others
Reply Quote Save Share Report
fiona_glasgow
Member
312
1,345
Aug 2024
Glasgow, UK
May 27, 2026 at 10:42 PM#18
FDA_TrackerJim said:
The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

True, and it depends on a baseline nobody has stated. Without knowing where someone started, the same number can be an excellent result or a disappointing one.

40 15KevinCompounds, TirzTom, TrialTracker_MD and 37 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
May 29, 2026 at 3:37 AM#19
FDA_TrackerJim said:
The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Genuinely useful, thank you. I had the facts and not the framework.

39 14FranDenver, Dr.BariatricHTX, LindaRN_retired and 36 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
May 30, 2026 at 8:32 AM#20

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Tagging this one for the weekly digest.

Last edited: May 30, 2026 at 10:32 AM
17 17PurityPaulOR, MaxMetOK, MounjBrad and 14 others
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register